Cosciens Biopharma INC. (CSCIF) — SEC Filings

Q: What are the key financial highlights for Cosciens Biopharma INC.?

Key financial highlights for Cosciens Biopharma INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Cosciens Biopharma INC.?

Key executives at Cosciens Biopharma INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Cosciens Biopharma INC. stock?

Risk factors for Cosciens Biopharma INC. (CSCIF) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Cosciens Biopharma INC.?

Forward-looking statements and predictions from Cosciens Biopharma INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Cosciens Biopharma INC.. Recent 6-K filing on Apr 20, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Cosciens Biopharma INC. on SEC EDGAR

Overview

Cosciens Biopharma INC. (CSCIF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 25, 2026: COSCIENS Biopharma Inc. filed a 6-K on March 25, 2026, indicating a routine report for a foreign issuer. This filing, with accession number 0001493152-26-012702, includes the 6-K form, an EX-99.1 exhibit, and a graphic. For investors, this filing itself doesn't contain new financial or operational n

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 1 bullish, 44 neutral. The dominant filing sentiment for Cosciens Biopharma INC. is neutral.

Filing Type Overview

Cosciens Biopharma INC. (CSCIF) has filed 39 6-K, 2 20-F, 1 SC 13D, 2 20-F/A, 1 SC 13G with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

6-K Filing — 6-K · Apr 20, 2026
COSCIENS Biopharma Files Routine 6-K Report on March 25, 2026 — 6-K · Mar 25, 2026
COSCIENS Biopharma Inc. filed a 6-K on March 25, 2026, indicating a routine report for a foreign issuer. This filing, with accession number 0001493152-26-012702
COSCIENS Biopharma inks China distribution deal for Macimorelin — 6-K · Dec 1, 2025 Risk: medium
On December 1, 2025, COSCIENS Biopharma Inc. announced an Exclusive Distribution Agreement with Wuzhou for its pharmaceutical product, Macimorelin. This agreeme
Cosciens Biopharma Files November 6-K Report — 6-K · Nov 14, 2025 Risk: low
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on November 14, 2025. The filing is a report of a foreign private issuer for the month
6-K Filing — 6-K · Nov 12, 2025
Cosciens Biopharma Files 6-K Report — 6-K · Aug 14, 2025 Risk: low
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on August 14, 2025. This report is for the month of August 2025 and indicates the comp
Cosciens Biopharma Files June 2025 6-K Report — 6-K · Jun 30, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on June 30, 2025, reporting for the month of June 2025. The company, formerly known as Aeterna Zentaris Inc. and Aetern
COSCIENS Biopharma Files June 2025 6-K Report — 6-K · Jun 9, 2025 Risk: low
COSCIENS Biopharma Inc. filed a Form 6-K on June 9, 2025, reporting for the month of June 2025. The company, formerly known as Aeterna Zentaris Inc. and AETERNA
Cosciens Biopharma Files May 2025 6-K Report — 6-K · Jun 2, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on May 30, 2025, reporting for the month of May 2025. The company, formerly known as Aeterna Zentaris Inc. and Aeterna
Cosciens Biopharma Files 6-K Report — 6-K · May 30, 2025 Risk: low
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on May 30, 2025. The filing is a report of a foreign private issuer and indicates the
Cosciens Biopharma Files Routine 6-K Report — 6-K · May 27, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on May 27, 2025. The company, formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc., is a foreign priva
Cosciens Biopharma Files 6-K Report — 6-K · May 20, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on May 20, 2025, reporting for the month of May 2025. The company, formerly known as Aeterna Zentaris Inc., is a foreig
Cosciens Biopharma Inc. Files 6-K Report — 6-K · May 13, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on May 13, 2025. The filing is a report of a foreign private issuer. The company was formerly known as Aeterna Zentaris
Cosciens Biopharma Files 6-K Report — 6-K · May 2, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on May 2, 2025, reporting as a foreign private issuer. The company, formerly known as Aeterna Zentaris Inc. and Aeterna
Cosciens Biopharma Inc. Files 6-K Report — 6-K · Apr 14, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on April 14, 2025, reporting as a foreign private issuer. The company, formerly known as Aeterna Zentaris Inc. and Aete
COSCIENS Biopharma Files 20-F, Details 2024 Financials — 20-F · Apr 9, 2025 Risk: medium
COSCIENS Biopharma Inc. filed its 20-F report for the fiscal year ending December 31, 2024. The company, formerly known as Aeterna Zentaris Inc., is in the phar
Cosciens Biopharma Files Routine 6-K — 6-K · Apr 2, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on April 2, 2025, reporting for the month of April 2025. The company, formerly known as Aeterna Zentaris Inc., is a for
Cosciens Biopharma Files 6-K Report — 6-K · Mar 20, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on March 20, 2025, reporting for the month of March 2025. The company, formerly known as Aeterna Zentaris Inc. and Aete
Cosciens Biopharma Files March 2025 6-K Report — 6-K · Mar 13, 2025 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on March 13, 2025. The filing is a report of a foreign private issuer for the month of March 2025. The company's princi
Cosciens Biopharma Files 6-K Report — 6-K · Dec 23, 2024 Risk: low
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on December 23, 2024. The filing is a report of a foreign private issuer for the month
Cosciens Biopharma Files Routine 6-K Report — 6-K · Nov 12, 2024 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on November 12, 2024, reporting for the month of November 2024. The company, formerly known as Aeterna Zentaris Inc., i
Cosciens Biopharma Files 6-K Report — 6-K · Oct 8, 2024 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on October 8, 2024, reporting for the month of October 2024. The company, formerly known as Aeterna Zentaris Inc. and A
Cosciens Biopharma Files 6-K for October 2024 — 6-K · Oct 1, 2024 Risk: low
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on October 1, 2024, for the month of October 2024. The filing indicates the company is
Cosciens Biopharma Files Routine 6-K Report — 6-K · Sep 23, 2024 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on September 23, 2024, reporting for the month of September 2024. The company, formerly known as Aeterna Zentaris Inc.
Goodwood Inc. Discloses 10.1% Stake in Cosciens Biopharma — SC 13D · Sep 6, 2024 Risk: medium
On September 6, 2024, Goodwood Inc. filed an SC 13D, reporting beneficial ownership of 10.1% of Cosciens Biopharma Inc. common stock. This filing indicates a si
Cosciens Biopharma Files 6-K Report — 6-K · Aug 27, 2024 Risk: low
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on August 27, 2024. The filing is a report of a foreign private issuer for the month o
Cosciens Biopharma Inc. Files Form 6-K — 6-K · Aug 13, 2024 Risk: low
Cosciens Biopharma Inc. filed a Form 6-K on August 13, 2024, reporting for the month of August 2024. The company, formerly known as Aeterna Zentaris Inc. and Ae
Aeterna Zentaris Files Form 6-K — 6-K · Aug 7, 2024 Risk: low
On August 6, 2024, Aeterna Zentaris Inc. filed a Form 6-K, reporting on events for the month of August 2024. The filing indicates the company is a foreign priva
Aeterna Zentaris Files 20-F/A Amendment — 20-F/A · Jul 17, 2024 Risk: medium
Aeterna Zentaris Inc. filed an amendment (20-F/A) on July 17, 2024, for its fiscal year ending December 31, 2023. The filing provides updated financial informat
Aeterna Zentaris Files June 2024 6-K Report — 6-K · Jun 25, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on June 25, 2024, reporting for the month of June 2024. The filing indicates the company is a foreign private issuer and
Aeterna Zentaris Files Form 6-K — 6-K · Jun 13, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on June 13, 2024, reporting as a foreign private issuer. The filing includes Exhibit 99.1, but the specific content of th
Aeterna Zentaris Files May 2024 6-K Report — 6-K · Jun 10, 2024 Risk: medium
Aeterna Zentaris Inc. filed a Form 6-K on June 10, 2024, reporting for the month of May 2024. The filing indicates that on June 3, 2024, the company made a sign
SC 13G Filing — SC 13G · Jun 6, 2024
Aeterna Zentaris Files May 2024 6-K Report — 6-K · May 17, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on May 17, 2024, reporting for the month of May 2024. The filing indicates the company is a foreign private issuer and fi
Aeterna Zentaris Files May 2024 6-K Report — 6-K · May 16, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on May 15, 2024, for the month of May 2024, reporting as a foreign private issuer. The company, previously known as AETER
Aeterna Zentaris Files 6-K with Exhibits — 6-K · May 15, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on May 15, 2024, reporting for the month of May 2024. The filing indicates that Exhibits 99.1 and 99.2 are included with
Aeterna Zentaris Issues Notice of Meeting and Record Date — 6-K · May 14, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on May 14, 2024, reporting its activities for May 2024. On May 9, 2024, the company issued a Notice of Meeting and Record
Aeterna Zentaris Completes 1-for-10 Share Consolidation — 6-K · May 9, 2024 Risk: low
Aeterna Zentaris Inc. filed a Form 6-K on May 9, 2024, reporting a material change related to the effectiveness of its previously announced share consolidation.
Aeterna Zentaris Announces Reverse Stock Split Effective Date — 6-K · May 1, 2024 Risk: low
Aeterna Zentaris Inc. announced on May 1, 2024, the effective date of its previously announced share consolidation, also known as a reverse stock split. This ac
Aeterna Zentaris Announces Final Court Approval for Combination — 6-K · Mar 28, 2024 Risk: medium
On March 28, 2024, Aeterna Zentaris Inc. announced the final court order approving its Plan of Arrangement to combine with Cellect Biotechnology Ltd. This plan
Aeterna Zentaris Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 27, 2024 Risk: low
Aeterna Zentaris Inc. (CSCIF) filed a Foreign Annual Report (20-F) with the SEC on March 27, 2024. Aeterna Zentaris Inc. filed its 20-F annual report on March 2
Aeterna Zentaris Shareholders Approve Ceapro Acquisition — 6-K · Mar 13, 2024 Risk: medium
Aeterna Zentaris Inc. announced on March 12, 2024, that its shareholders, along with those of Ceapro Inc., approved the previously announced acquisition of Ceap
ISS Recommends on Aeterna-Ce Arrangement — 6-K · Feb 27, 2024 Risk: medium
Aeterna Zentaris Inc. announced on February 26, 2024, that proxy advisory firm ISS has issued its recommendations concerning Aeterna's previously disclosed Spec
Aeterna Zentaris Files Proxy for Special Shareholder Meeting — 6-K · Feb 20, 2024 Risk: medium
Aeterna Zentaris Inc. (Aeterna) published a Notice of Special Meeting of Shareholders and Management Proxy Circular on February 15, 2024. This filing relates to
Aeterna Zentaris Inc. Files 20-F/A Amendment — 20-F/A · Feb 15, 2024 Risk: low
Aeterna Zentaris Inc. (CSCIF) filed a Amended Foreign Annual Report (20-F/A) with the SEC on February 15, 2024. Filing is an amendment (20-F/A) to a previous fi

Risk Profile

Risk Assessment: Of CSCIF's 41 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 32 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Peter Puccetti

Industry Context

Aeterna Zentaris Inc. operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, regulatory oversight, and market competition.

Top Tags

foreign-private-issuer (22) · regulatory-filing (12) · reporting (12) · 6-K (7) · sec-filing (5) · corporate-action (5) · compliance (4) · corporate-update (4) · company-name-change (3) · pharmaceutical (3)

Key Numbers

SEC File Number: 001-38064 — Identifies the company's registration with the SEC.
Filing Date: 20250502 — Date of the 6-K submission
Central Index Key: 0001113423 — Unique identifier for the company in SEC filings
Fiscal Year End: 2024-12-31 — The primary reporting period covered by the 20-F filing.
Previous Fiscal Year End: 2023-12-31 — Provides comparative financial data.
Prior Fiscal Year End: 2022-12-31 — Provides further comparative financial data.
Ownership Stake: 10.1% — Percentage of Cosciens Biopharma Inc. common stock beneficially owned by Goodwood Inc.
Share Consolidation Ratio: 1-for-10 — Indicates a reverse stock split where 10 old shares become 1 new share.
SIC Code: 2834 — Pharmaceutical Preparations.
Commission File Number: 001-38064 — identifies the filing with the SEC
Conformed Period of Report: 20240216 — indicates the period covered by the report

Related Companies

AEZS

Frequently Asked Questions

What are the latest SEC filings for Cosciens Biopharma INC. (CSCIF)?

Cosciens Biopharma INC. has 45 recent SEC filings from Feb 2024 to Apr 2026, including 39 6-K, 2 20-F, 2 20-F/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CSCIF filings?

Across 45 filings, the sentiment breakdown is: 1 bullish, 44 neutral. The dominant sentiment is neutral.

Where can I find Cosciens Biopharma INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cosciens Biopharma INC. (CSCIF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cosciens Biopharma INC.?

Financial highlights for Cosciens Biopharma INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for CSCIF?

The investment thesis for CSCIF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cosciens Biopharma INC.?

Key executives identified across Cosciens Biopharma INC.'s filings include Peter Puccetti.

What are the main risk factors for Cosciens Biopharma INC. stock?

Of CSCIF's 41 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 32 low-risk.

What are recent predictions and forward guidance from Cosciens Biopharma INC.?

Forward guidance and predictions for Cosciens Biopharma INC. are extracted from SEC filings as they are enriched.